Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database. Issue 6 (22nd June 2019)

• Record Type: Journal Article
• Authors: Zhuo, Lin; Cheng, Yinchu; Pan, Yuting; Zong, Jihong; Sun, Wentao; Xu, Lin; Soriano-Gabarró, Montse; Song, Yi; Lu, Jian; Zhan, Siyan
• Is Part Of: BMJ open. Volume 9:Issue 6(2019)
• Publication Date: 2019-06-22
• Subjects: prostate cancer with bone metastasis -- prevalence -- administrative claims database -- treatment costs; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2018-028214
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To estimate the prevalence of prostate cancer with bone metastasis in Beijing, and to estimate hospital visits and direct treatment costs among male urban employees with the disease in Beijing. Design: Cross-sectional observational study. Setting and participants: Patients with prostate cancer and bone metastasis from the Urban Employee Basic Medical Insurance database covering the employed population of Beijing, China, from 2011 to 2014. Primary and secondary outcome measures: Prevalence, treatment costs and healthcare visits of patients with prostate cancer and bone metastasis. Results: A total of 1672 individuals were identified as having prostate cancer. Of these, 737 (44.1%) had bone metastasis, and among these, this was already present at the time of initial prostate cancer diagnosis in 27.0% (199/737). Mean age was 74.6 years (SD ±9.1). Prevalence of prostate cancer with bone metastasis increased from 5.3 per 100 000 males in 2011 to 8.3 per 100 000 males in 2014. The total annual health expenditure per patient (in 2014 American dollars) during the study period was $15 772.1 (SD=$16 942.6) ~$18 206.3 (SD=$18 700.2); 88% of these costs were reimbursed by insurance. Medication accounted for around 50% of total healthcare costs. Western drugs accounted for over 80% of medical costs with endocrine therapy being the most commonly prescribed treatment. There was an average 6.7% increase in expenditure related to diagnostical and therapeutical procedures over study years. Conclusions: The increase in the prevalence of prostate cancer with bone metastasis and associated healthcare costs in China reveals the growing clinical and economical burden of this disease. The high prevalence of bone metastasis among patients with prostate cancer seen in our study suggests that efforts may be needed to improve symptoms awareness and promote early help-seeking behaviour among the Chinese population.